Showing results (131-140 of 156) with videos related to
Sort By:
Pageof 16
JAMA Oncology|September 28, 2023
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled TrialTae Won Kim, Philippe L Bedard, Patricia LoRusso, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 27, 2023
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced SarcomaCiara M Kelly, Li-Xuan Qin, Karissa A Whiting, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue SarcomaMrinal M Gounder, Alona Zer, William D Tap, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with SarcomaSujana Movva, Kenneth Seier, Viswatej Avutu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2022
Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal TumorsPing Chi, Li-Xuan Qin, Niedzica Camacho, et al.European Journal of Cancer (Oxford, England : 1990)|October 10, 2022
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgeryEvan Rosenbaum, Rashmi Chugh, Christopher W Ryan, et al.The Lancet. Oncology|March 22, 2015
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialJeffrey S Weber, Sandra P D'Angelo, David Minor, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2025
Circulating tumor DNA as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with advanced gastrointestinal stromal tumorsCiara M Kelly, Martina Bradic, Sara Saunds, et al.Nature Cancer|March 1, 2024
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapyAjay Subramanian, Neda Nemat-Gorgani, Timothy J Ellis-Caleo, et al.Journal for Immunotherapy of Cancer|October 26, 2019
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcomaIndu Ramachandran, Daniel E Lowther, Rebecca Dryer-Minnerly, et al.Pageof 16